NASDAQ:FOLD
Amicus Therapeutics Stock News
$9.23
-0.250 (-2.64%)
At Close: May 10, 2024
Analysts Are Updating Their Amicus Therapeutics, Inc. (NASDAQ:FOLD) Estimates After Its First-Quarter Results
01:50pm, Sunday, 10'th May 2020
It's been a good week for Amicus Therapeutics, Inc. (NASDAQ:FOLD) shareholders, because the company has just released...
Amicus Therapeutics Inc (FOLD) Q1 2020 Earnings Call Transcript
05:31pm, Saturday, 09'th May 2020
FOLD earnings call for the period ending March 31, 2020.
7 “Strong Buy” Healthcare Stocks to Buy Now
03:46pm, Friday, 08'th May 2020
As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
11:00am, Friday, 08'th May 2020
Amicus Therapeutics (FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020 Annual
'There is no future': the refugees who became pawns in Erdoğan’s game
06:15am, Friday, 08'th May 2020
First the asylum seekers were used to further Turkey’s regional ambitions, now they are made to suffer in quarantine camps
Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT
05:11am, Friday, 08'th May 2020
Q1 2020 Amicus Therapeutics Inc Earnings Call
Fairmount Funds Management LLC Buys Zogenix Inc, Amicus Therapeutics Inc, Axsome Therapeutics ...
12:00am, Friday, 08'th May 2020Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
01:25pm, Thursday, 07'th May 2020
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
12:57pm, Thursday, 07'th May 2020Amicus Therapeutics Q1 EPS $(0.350) Misses $(0.280) Estimate, Sales $60.500M Beat $57.490M Estimate
11:30am, Thursday, 07'th May 2020Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
11:00am, Thursday, 07'th May 2020
Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA in.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
11:00am, Wednesday, 06'th May 2020
Amicus Therapeutics (FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of sever
UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene ...
12:00am, Wednesday, 06'th May 2020Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
11:00am, Tuesday, 05'th May 2020
Amicus Therapeutics (FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of sever
